FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Gwynn Ison et al.|Clinical Cancer Research|2015Cited by 532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerJulia A. Beaver, Patricia Cortazar, Laleh Amiri‐Kordestani et al.|Clinical Cancer Research|2015Cited by 377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Gideon M. Blumenthal et al.|Clinical Cancer Research|2014Cited by 350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2Qin Ryan, Richard Pazdur, Amna Ibrahim et al.|The Oncologist|2008Cited by 310